CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
快照：癌症治疗的特征
英文原题：SnapShot: The hallmarks of cancer treatment.
查看英文原题
SnapShot: The hallmarks of cancer treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症治疗从细胞毒性化疗发展到由分子谱分析指导的靶向治疗和免疫治疗。早期细胞毒性药物源于芥子气的观察，仍然有效但具有毒性。靶向药物利用致癌弱点，但通常选择耐药克隆。检查点抑制剂和工程化治疗模式（ADC、BiTE、CAR-T）可产生缓解，但受限于毒性和适应性抗原丢失。未来的治疗组合将需要靶向耐药性的演变。要查看本 SnapShot，请打开或下载 PDF。
展开英文摘要原文
Cancer therapy evolved from cytotoxic chemotherapy to targeted and immune treatments guided by molecular profiling. Early cytotoxic drugs, rooted in mustard-gas observations, remain effective but toxic. Targeted agents exploit oncogenic vulnerabilities yet commonly select resistant clones.
Checkpoint inhibitors and engineered modalities (ADCs, BiTEs, CAR-T) yield responses but are limited by toxicity and adaptive antigen loss. Future treatment combinations will require targeting the evolution of resistance. To view this SnapShot, open or download the PDF.
论文信息
- 作者
- Vitiello PP、Amodio V、Bardelli A
- 第一作者单位
- IFOM ETS - The AIRC Institute of Molecular Oncology, 20139 Milan, Italy.Italy
- 通讯作者单位
- IFOM ETS - The AIRC Institute of Molecular Oncology, 20139 Milan, Italy; Department of Oncology, Molecular Biotechnology Center, University of Torino, 10126 Turin, Italy. Electronic address: alberto.bardelli@unito.it.Italy
- 期刊
- Cell2026 Apr 16
- 原文标识
- PubMed 41997133 · DOI 10.1016/j.cell.2026.03.017